During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout. In the healthcare sector, there are several high-yielding stocks that have caught the attention of Wall Street analysts.
One such stock is Pfizer Inc. (PFE), which currently has a dividend yield of 6.23%. Cantor Fitzgerald analyst Louise Chen recently reiterated an Overweight rating on the stock with a price target of $45. Chen has an accuracy rate of 66%, making her one of the most accurate analysts in the field. On the other hand, TD Cowen analyst Steve Scala downgraded the stock from Outperform to Market Perform with a price target of $32. Scala has an accuracy rate of 73%. In recent news, Pfizer expanded its agreement with Saama to integrate AI-driven data solutions across its R&D portfolio.
Another high-yielding stock in the healthcare sector is Bristol-Myers Squibb Company (BMY), which currently has a dividend yield of 4.93%. Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating on the stock and lowered the price target from $58 to $51. Bansal has an accuracy rate of 77%. B of A Securities analyst Geoff Meacham downgraded the stock from Buy to Neutral and cut the price target from $68 to $60. Meacham has an accuracy rate of 61%. Bristol-Myers Squibb reported fourth-quarter revenues of $11.48 billion, beating the consensus estimate, primarily due to higher sales of its new product portfolio.
Gilead Sciences, Inc. (GILD) is another high-yielding stock in the healthcare sector, with a dividend yield of 4.19%. RBC Capital analyst Brian Abrahams maintained a Sector Perform rating on the stock and cut the price target from $78 to $76. Abrahams has an accuracy rate of 73%. Wells Fargo analyst Mohit Bansal also maintained an Equal-Weight rating on the stock and slashed the price target from $90 to $84. Bansal has an accuracy rate of 77%. Gilead Sciences recently agreed to acquire CymaBay Therapeutics for $4.3 billion.
Investors interested in dividend-yielding stocks in the healthcare sector should take note of these analyst ratings. It’s important to consider the accuracy rate of analysts when making investment decisions. By reviewing the latest analyst takes on high-yield dividend stocks, investors can make more informed choices about their portfolios.
In conclusion, during times of market turbulence, dividend-yielding stocks in the healthcare sector can provide stability and income for investors. Pfizer Inc., Bristol-Myers Squibb Company, and Gilead Sciences, Inc. are three high-yielding stocks that have recently received attention from Wall Street analysts. By considering the ratings and accuracy rates of these analysts, investors can make informed decisions about their investments.
